{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:12:34Z","timestamp":1791807154300,"version":"4.3.4"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Melinta Therapeutics, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality. Rezafungin is a second-generation echinocandin with antifungal activity against a range of Candida species, including wild type, and azole- and some echinocandin-resistant isolates. Its stability and prolonged half-life permit less frequent dosing compared with other echinocandins, leading to high front-loaded exposures and potential earlier mycological clearance from infection sites. These properties make rezafungin a candidate for the treatment of candidemia and invasive candidiasis infections due to C. auris. Accordingly, this narrative review article describes available evidence for the activity and effectiveness of rezafungin against C. auris isolates and infections. To date, the activity of rezafungin against C. auris isolates and infections has been demonstrated in in vitro and in vivo non-clinical experiments, and in pharmacokinetic\/pharmacodynamic target attainment estimations utilizing clinical data. With similar potency to other echinocandins, rezafungin demonstrates in vitro and in vivo activity that is comparable to or better than that seen with other echinocandins, and similar to that for rezafungin in other Candida species. Like other echinocandins, its activity is reduced in fks-mutant isolates. Although there is currently a dearth of data on the therapeutic activity of rezafungin against C. auris, it is reasonable that rezafungin may be a viable choice for treating candidemia and invasive candidiasis caused by C. auris. Further clinical investigations are necessary.<\/jats:p>","DOI":"10.1093\/jac\/dkaf124","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:41:45Z","timestamp":1744476105000},"page":"1482-1493","source":"Crossref","is-referenced-by-count":15,"title":["Activity of rezafungin against\n                    <i>Candida auris<\/i>"],"prefix":"10.1093","volume":"80","author":[{"given":"Jeffrey B","family":"Locke","sequence":"first","affiliation":[{"name":"Cidara Therapeutics, Inc. , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":false,"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , Madison, WI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc. , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-4345","authenticated-orcid":false,"given":"Mark","family":"Redell","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, LLC , Parsippany, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc. , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal A","family":"Aram","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, LLC , Parsippany, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California Davis Medical Center , Sacramento, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2025060219530102300_dkaf124-B1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2025060219530102300_dkaf124-B2","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1093\/cid\/ciaa193","article-title":"Burden of candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025060219530102300_dkaf124-B3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/microorganisms12050927","article-title":"Candida auris outbreaks: current status and future perspectives","volume":"12","author":"De Gaetano","year":"2024","journal-title":"Microorganisms"},{"key":"2025060219530102300_dkaf124-B4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/MCC.0000000000001077","article-title":"Treatment of invasive candidiasis in the era of Candida resistance","volume":"29","author":"Paiva","year":"2023","journal-title":"Curr Opin Crit Care"},{"key":"2025060219530102300_dkaf124-B5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2174\/1568026618666180528121707","article-title":"Emerging virulence, drug resistance and future anti-fungal drugs for Candida pathogens","volume":"18","author":"Srivastava","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"2025060219530102300_dkaf124-B6","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.1002\/mbo3.578","article-title":"Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen","volume":"7","author":"Osei Sekyere","year":"2018","journal-title":"Microbiologyopen"},{"key":"2025060219530102300_dkaf124-B7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/biomedicines12030561","article-title":"Pathogenesis, prophylaxis, and treatment of Candida auris","volume":"12","author":"Preda","year":"2024","journal-title":"Biomedicines"},{"key":"2025060219530102300_dkaf124-B8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/ejhpharm-2020-002604","article-title":"Antifungal drug resistance: an update","volume":"29","author":"Denning","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"2025060219530102300_dkaf124-B9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/biomedicines11041063","article-title":"Antifungal drug resistance: an emergent health threat","volume":"11","author":"Vitiello","year":"2023","journal-title":"Biomedicines"},{"key":"2025060219530102300_dkaf124-B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40560-018-0342-4","article-title":"Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris","volume":"6","author":"Cortegiani","year":"2018","journal-title":"J Intensive Care"},{"key":"2025060219530102300_dkaf124-B11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13054-019-2449-y","article-title":"The global challenge of Candida auris in the intensive care unit","volume":"23","author":"Cortegiani","year":"2019","journal-title":"Crit Care"},{"key":"2025060219530102300_dkaf124-B12","doi-asserted-by":"publisher","first-page":"2200846","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200846","article-title":"Increasing number of cases and outbreaks caused by Candida auris in the EU\/EEA, 2020 to 2021","volume":"27","author":"Kohlenberg","year":"2022","journal-title":"Euro Surveill"},{"key":"2025060219530102300_dkaf124-B13","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025060219530102300_dkaf124-B14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/jgid.jgid_215_22","article-title":"State of the globe: Candida auris\u2013a global healthcare threat","volume":"14","author":"Thakur","year":"2022","journal-title":"J Glob Infect Dis"},{"key":"2025060219530102300_dkaf124-B15","volume-title":"WHO fungal Priority Pathogens List to Guide Research, Development and Public Health Action","author":"World Health Organization","year":"2022"},{"key":"2025060219530102300_dkaf124-B16","volume-title":"Tracking C. auris","author":"US Centers for Disease Control and Prevention","year":"2024"},{"key":"2025060219530102300_dkaf124-B17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/jof9090913","article-title":"An overview on Candida auris in healthcare settings","volume":"9","author":"Cristina","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2025060219530102300_dkaf124-B18","doi-asserted-by":"publisher","first-page":"658329","DOI":"10.3389\/fmicb.2021.658329","article-title":"Retrospective analysis of the clinical characteristics of Candida auris infection worldwide from 2009 to 2020","volume":"12","author":"Hu","year":"2021","journal-title":"Front Microbiol"},{"key":"2025060219530102300_dkaf124-B19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025060219530102300_dkaf124-B20","doi-asserted-by":"publisher","first-page":"e1008921","DOI":"10.1371\/journal.ppat.1008921","article-title":"Candida auris: epidemiology, biology, antifungal resistance, and virulence","volume":"16","author":"Du","year":"2020","journal-title":"PLoS Pathog"},{"key":"2025060219530102300_dkaf124-B21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1017\/ice.2017.162","article-title":"Effectiveness of disinfectants against Candida auris and other Candida species","volume":"38","author":"Cadnum","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025060219530102300_dkaf124-B22","doi-asserted-by":"publisher","first-page":"e1010954","DOI":"10.1371\/journal.ppat.1010954","article-title":"Ploidy changes in human fungal pathogens: going beyond sexual reproduction","volume":"18","author":"Du","year":"2022","journal-title":"PLoS Pathog"},{"key":"2025060219530102300_dkaf124-B23","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1128\/JCM.00319-11","article-title":"First three reported cases of nosocomial fungemia caused by Candida auris","volume":"49","author":"Lee","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2025060219530102300_dkaf124-B24","doi-asserted-by":"publisher","first-page":"e0057024","DOI":"10.1128\/aac.00570-24","article-title":"Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization","volume":"68","author":"Castanheira","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","article-title":"Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital","volume":"53","author":"Satoh","year":"2009","journal-title":"Microbiol Immunol"},{"key":"2025060219530102300_dkaf124-B26","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3201\/eid2509.190686","article-title":"Potential fifth clade of Candida auris, Iran, 2018","volume":"25","author":"Chow","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2025060219530102300_dkaf124-B27","doi-asserted-by":"publisher","first-page":"e0354023","DOI":"10.1128\/spectrum.03540-23","article-title":"Emergence of the novel sixth Candida auris Clade VI in Bangladesh","volume":"12","author":"Khan","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2025060219530102300_dkaf124-B28","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/S2666-5247(24)00101-0","article-title":"Detection and characterisation of a sixth Candida auris clade in Singapore: a genomic and phenotypic study","volume":"5","author":"Suphavilai","year":"2024","journal-title":"Lancet Microbe"},{"key":"2025060219530102300_dkaf124-B29","doi-asserted-by":"publisher","first-page":"e03364-19","DOI":"10.1128\/mBio.03364-19","article-title":"Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses","volume":"11","author":"Chow","year":"2020","journal-title":"mBio"},{"key":"2025060219530102300_dkaf124-B30","doi-asserted-by":"publisher","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B31","volume-title":"Antifungal Susceptibility Testing for C. auris","author":"US Centers for Disease Control and Prevention","year":"2024"},{"key":"2025060219530102300_dkaf124-B32","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025060219530102300_dkaf124-B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025060219530102300_dkaf124-B34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/jof10050362","article-title":"A mini-review of in vitro data for Candida species, including C. auris, isolated during clinical trials of three new antifungals: fosmanogepix, ibrexafungerp, and rezafungin","volume":"10","author":"Espinel-Ingroff","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2025060219530102300_dkaf124-B35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.diagmicrobio.2017.10.021","article-title":"Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris","volume":"90","author":"Berkow","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025060219530102300_dkaf124-B36","doi-asserted-by":"publisher","first-page":"e0244921","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025060219530102300_dkaf124-B37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.diagmicrobio.2017.07.007","article-title":"In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp","volume":"89","author":"Hall","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025060219530102300_dkaf124-B38","doi-asserted-by":"publisher","first-page":"e02438-19","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B39","doi-asserted-by":"publisher","first-page":"e01556-19","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B40","doi-asserted-by":"publisher","first-page":"e02154","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B41","doi-asserted-by":"publisher","first-page":"e00099-20","DOI":"10.1128\/AAC.00099-20","article-title":"Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY program, 2016 to 2018)","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B42","doi-asserted-by":"publisher","first-page":"e02045-16","DOI":"10.1128\/AAC.02045-16","article-title":"Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 antifungal surveillance program","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B43","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B44","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2025060219530102300_dkaf124-B45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 antifungal surveillance program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025060219530102300_dkaf124-B46","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B47","doi-asserted-by":"publisher","first-page":"e01626-16","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin CD101 in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B48","doi-asserted-by":"publisher","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2025060219530102300_dkaf124-B50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/jac\/dkae415","article-title":"The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics","volume":"80","author":"Andes","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2025060219530102300_dkaf124-B52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025060219530102300_dkaf124-B53","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025060219530102300_dkaf124-B54","doi-asserted-by":"publisher","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B55","doi-asserted-by":"publisher","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B56","volume-title":"Mundipharma Announces European Approval of REZZAYO\u00ae (Rezafungin) for the Treatment of Invasive Candidiasis in Adults","author":"Mundipharma","year":"2023"},{"key":"2025060219530102300_dkaf124-B57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/infdis\/jiae146","article-title":"Regulatory considerations in the approval of rezafungin (REZZAYO) for the treatment of candidemia and invasive candidiasis in adults","volume":"230","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"2025060219530102300_dkaf124-B58","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B59","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/microorganisms9040863","article-title":"Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in RPMI-1640 in the absence and presence of human serum","volume":"9","author":"Kov\u00e1cs","year":"2021","journal-title":"Microorganisms"},{"key":"2025060219530102300_dkaf124-B60","volume-title":"Susceptibility of Recent Candida auris Isolates to the Novel Echinocandin CD101 and Comparator Antifungal Agents","author":"Larkin","year":"2017"},{"key":"2025060219530102300_dkaf124-B61","doi-asserted-by":"publisher","first-page":"ofad500.1738","DOI":"10.1093\/ofid\/ofad500.1738","article-title":"2115. Rezafungin activity against invasive candidiasis isolates globally: results from the 2022 rezafungin surveillance program","volume":"10","author":"Carvalhaes","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025060219530102300_dkaf124-B62","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1111\/myc.70001","article-title":"The in vitro activity of rezafungin against uncommon species of Candida","volume":"67","author":"Winkler","year":"2024","journal-title":"Mycoses"},{"key":"2025060219530102300_dkaf124-B63","doi-asserted-by":"publisher","first-page":"e00659-19","DOI":"10.1128\/AAC.00659-19","article-title":"EUCAST reference testing of rezafungin susceptibility and impact of choice of plastic plates","volume":"63","author":"Arendrup","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B64","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Fourth Edition: M27","author":"CLSI","year":"2017"},{"key":"2025060219530102300_dkaf124-B65","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Third Edition: M27-A3","author":"CLSI","year":"2008"},{"key":"2025060219530102300_dkaf124-B66","volume-title":"EUCAST definitive Document E.DEF 7.3.1. Method for the Determination of Broth Dilution minimum Inhibitory Concentrations of Antifungal Agents for Yeasts","author":"Arendrup","year":"2017"},{"key":"2025060219530102300_dkaf124-B67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/jac\/dkac373","article-title":"Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin","volume":"78","author":"Arendrup","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B68","volume-title":"EUCAST definitive Document E.Def 7.4. Method for the Determination of Broth Dilution minimum Inhibitory Concentrations of Antifungal Agents for Yeasts","author":"Guinea","year":"2023"},{"key":"2025060219530102300_dkaf124-B69","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/jac\/dkad055","article-title":"Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin","volume":"78","author":"Zuill","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"2025060219530102300_dkaf124-B71","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025060219530102300_dkaf124-B72","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/jof10090617","article-title":"In vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against four Candida auris clades in a neutropenic murine bloodstream infection model","volume":"10","author":"Bal\u00e1zsi","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2025060219530102300_dkaf124-B73","doi-asserted-by":"publisher","first-page":"e02614-17","DOI":"10.1128\/AAC.02614-17","article-title":"Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata","volume":"62","author":"Bader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B74","doi-asserted-by":"publisher","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B75","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1128\/AAC.45.12.3322-3327.2001","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B76","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1128\/AAC.01596-07","article-title":"Pharmacokinetics and tissue distribution of anidulafungin in rats","volume":"52","author":"Damle","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B77","doi-asserted-by":"publisher","first-page":"106553","DOI":"10.1016\/j.ijantimicag.2022.106553","article-title":"Human tissue distribution of caspofungin","volume":"59","author":"Marx","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025060219530102300_dkaf124-B78","doi-asserted-by":"publisher","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2025060219530102300_dkaf124-B79","doi-asserted-by":"publisher","first-page":"e0091623","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219530102300_dkaf124-B80","volume-title":"Rationale for EUCAST Clinical Breakpoints. Version 1.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2024"},{"key":"2025060219530102300_dkaf124-B81","author":"Redell"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1482\/63032644\/dkaf124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1482\/63032644\/dkaf124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:53:12Z","timestamp":1748893992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/6\/1482\/8122730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf124","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,30]]}}}